Companion Diagnostics for Oncology Market Size, Share, Development by 2027
A companion diagnostic is an in vitro diagnostic medical
kit. Through this test, healthcare professionals can determine whether a
particular therapeutic product is effective for the patient or possess any
serious side effects or risks. The key factors driving the market growth are
increasing R&D and drug-diagnostic co-development, growing preference for
personalized medicine, increasing global incidence of cancer, and increasing
product approvals by major players. However, the lack of reimbursement in
developing regions may hamper the market growth. The entry of market players in
emerging economies creates growth opportunities for the companion diagnostics
for the oncology market.
Global Companion
Diagnostics for Oncology Market is expected to register a CAGR of 22.57%
during the forecast period and is expected to hit USD 5,064.17 Million by 2027.Major
market players are focusing on various growth strategies such as product
launches, product advancements, and business expansions to cater to the growing
need for personalized medicine. These product launches and business expansion
drive the growth of the companion diagnostics for oncology market. For
instance, in March 2020, Thermo Fisher signed a strategic agreement with
Janssen Services to co-develop a companion diagnostic product related to
oncology, which will support clinical trial enrollment globally. Similarly, in
March 2019, Roche launched the Ventana PD-L1 (SP142) Assay in Europe as the
first companion diagnostic to identify triple-negative breast cancer patients
eligible for treatment with Tecentriq. Furthermore, in March 2019, Roche received
the US FDA approval for its Ventana PD-L1 (SP142) assay approved as the first
companion diagnostic to identify triple-negative breast cancer patients
eligible for the treatment with Tecentriq in combination with Abraxane.
Request
Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/10422
Segment Analysis
Global Companion Diagnostics for Oncology Market has been
segmented based on products & services, technology, indication, and end
user. The market, on the basis of products & services, has been segmented
into assays, kits & reagents and software & services.
Based on technology, the global companion diagnostics for
oncology market is segmented into polymerase chain reaction (PCR) and
next-generation sequencing (NGS). The global market, on the basis of
indication, has been segmented into breast cancer, lung cancer, colorectal
cancer, gastric cancer, melanoma, and others.
Regional Analysis
Global Companion Diagnostics for Oncology Market, based on
region, is segmented into four main regions, including the Americas, Europe,
Asia-Pacific, and the Middle East & Africa. The Americas is accounted for a
major market share in 2019, whereas Asia-Pacific is projected to be the
fastest-growing regional market during the forecast period.
In the global companion diagnostics for oncology market, the
Americas held the largest share of 37.3% in 2019. The market growth in the
Americas is due to the high prevalence rate of cancer and rising healthcare
expenditure. According, to the National Institutes of Health, it was estimated
that 1,735,350 new cases of cancer were diagnosed in the US in 2018. Europe
acquired the second-largest market share in 2019. The Europe market is expected
to register a sturdy growth rate during the forecast period due to the presence
of a large number of companies, growing research and development activity to
develop targeted drug therapy for a cancer patient, and the rising per capita
income increasing the preference for personalized medicine. According to the
European Journal of Cancer, there were around 3.9 million new cases and 1.9
million deaths from cancer in Europe in 2018. The increasing cancer population
supports market growth in this region.
Asia-Pacific is anticipated to be the fastest-growing
regional market during the forecast period. The rapid growth of the
Asia-Pacific market is due to the growing number of cancer patients and rising
presence of market players. According to the Global Cancer Observatory, around
1,157,294 cases of cancer were reported in India in 2018. Additionally,
increasing research funding, rising investments by pharmaceutical and
biotechnology companies, and growing awareness about personalized therapeutics
in several APAC countries are expected to drive the growth of the regional
market. The Middle East and Africa accounted for the least market of USD 82.64
million in 2019. The companion diagnostics for oncology market in countries
such as Kuwait, the UAE, and Saudi Arabia are likely to show steady growth due
to increasing cancer cases, rising drug discovery, and increasing preference
for personalized medicines. Also, the growing number of hospitals, research
laboratories, and increasing investment by healthcare companies in this region
drives the growth of CDx in the Middle East & African countries.
Key Players
MRFR recognizes the following companies as the Key Players
in the global Companion Diagnostics for Oncology Market— Agilent Technologies
Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland),
BioMérieux SA (France), Foundation Medicine (US), Archer Dx (US), Qiagen
(Germany), Thermo Fisher Scientific Inc. (US), and Amoy Dx (China) and Abbott
Laboratories (US).
Key Findings of the Study
Global Companion Diagnostics for Oncology Market was valued
at USD 1,603.16 Million in 2019 and is expected to register a CAGR of 57%
during the forecast period of 2020 to 2027
The Americas accounted for the largest share of the global
market due to the high prevalence rate of cancer and other chronic disorders
and rising healthcare expenditure. These factors are driving the growth of
companion diagnostics for oncology market in the region.
Based on the products & services, the market is divided
into the assays, kits & reagents and software & services is expected to
account for a major share in the global companion diagnostics for oncology
market share of 62.11% in 2019
On the basis of indication, the others segment dominated the
global companion diagnostics for oncology market by revenue in 2019. The
treatment segment accounted for the largest value of USD 73 in 2019; it is
expected to register a CAGR of 22.57% during the forecast period.
Based on end-user, the pharmaceutical &
biopharmaceutical companies accounted for the largest market share of 38.19% in
2019
Browse Detailed TOC
with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/companion-diagnostics-oncology-market-10422
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Comments
Post a Comment